LISATA THERAPEUTICS, INC. Share-based Payment Arrangement, Accelerated Cost
LISATA THERAPEUTICS, INC. (LSTA) reported Share-based Payment Arrangement, Accelerated Cost of $1.90 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2019-03-14
- LISATA THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2017-09-30 was $1.90M.
- LISATA THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2017-06-30 was $1.90M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month |
|---|---|---|---|
| 2017-09-30 | $1.90M 10-Q · filed 2017-11-09 | $3.80M derived: sum of 2 quarters · filed 2018-11-08 | $1.90M 10-K · filed 2019-03-14 |
| 2017-06-30 | $1.90M 10-Q · filed 2018-11-08 | $1.90M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |